Drug intelligence / Profile preview

rocavorexant

Development stage: Phase 2
Lead developer: Janssen Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Rocavorexant (formerly JNJ-61393215 or MAV-201) is a small molecule dual orexin receptor antagonist (DORA) being developed for the treatment of major depressive disorder (MDD). Developed by Janssen Pharmaceuticals in collaboration with Minerva Neurosciences, it targets both orexin-1 (OX1) and orexin-2 (OX2) receptors. Unlike traditional antidepressants, rocavorexant modulates the orexin system, which is involved in regulating wakefulness, arousal, and reward pathways. By blocking these receptors, it aims to improve symptoms of depression, particularly in patients with comorbid insomnia or those who have not responded to standard therapies.

Other names: rocavorexant

Targets

HCRTR1 (Orexin/hypocretin receptor type 1)HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on rocavorexant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rocavorexant.

Explore the full profile